Real-world data vital to advancing cancer research according to recent survey

• The study of 200 practicing oncologists in the United States also found that oncologists believe it is important for all clinical trials to include a real-world data component, and the overwhelming majority (78 percent) would urge pharmaceutical companies and cancer research groups to use real-world data in all clinical trials
• The study also highlighted a few particular areas where oncologists’ perceptions differed from that of patients’ and from industry realities, including:need for more diversity in cancer clinical trials, a growing patient expectation for better cancer treatments, faster
• “The (COVID-19) pandemic highlighted the vital benefit real-world data can have when it comes to ensuring the efficacy and safety of swiftly developed vaccines aimed at decreasing the impact of COVID-19, … It is not surprising that providers and patients now want to see the same turnaround time for cancer drugs and treatments. Real-world data is one solution to this challenge of speeding cancer-specific innovation.“

C.K. Wang, MD, Chief Medical Officer at COTA, Inc.

Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

ref: JAN2022BS002